HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism (Q40252395)

18 September 2017

HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism (English)

1 reference

18 September 2017

1 reference

3

Martin Wabitsch

0 references

author name string

Roy J Kim

1

1 reference

18 September 2017

Camella G Wilson

2

1 reference

18 September 2017

Mitchell A Lazar

4

1 reference

18 September 2017

Claire M Steppan

5

1 reference

18 September 2017

1 June 2006

1 reference

18 September 2017

1 reference

18 September 2017

14

1 reference

18 September 2017

6

1 reference

18 September 2017

994-1002

1 reference

Abnormal fat distribution and use of protease inhibitors

18 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Protease inhibitors and cardiovascular outcomes in patients with HIV-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Trends in Rates of Myocardial Infarction among Patients with HIV

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

An open-label, prospective, observational study of the incidence of coronary artery disease in patients with hiv infection receiving highly active antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Therapeutic dose of HIV-1 protease inhibitor saquinavir does not permanently influence early insulin signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Inhibition of adipocyte differentiation by HIV protease inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

HIV protease inhibitors block adipogenesis and increase lipolysis in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

HIV protease inhibitor ritonavir induces lipoatrophy in male mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Visceral abdominal-fat accumulation associated with use of indinavir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Select HIV protease inhibitors alter bone and fat metabolism ex vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Indinavir induces acute and reversible peripheral insulin resistance in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Adiponectin and adiponectin receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.114

31 March 2020

Identifiers

DOI

10.1038/OBY.2006.114

1 reference

18 September 2017

1 reference